This description is a summary of our understanding of the job description. Click on 'Apply' button to find out more.

Role Description

The US Director, HEOR & RWE will lead the design, execution, and communication of health, economic and outcomes research strategies supporting the company’s global metabolic health portfolio. This leader will generate high-quality real-world, clinical, and economic evidence to demonstrate product value to payers, providers, patients, and policymakers. The role requires expertise in value demonstration, real-world data (RWD), and outcomes modeling, as well as the ability to translate complex data into actionable insights for commercial and clinical decision-making. Remote location, ideally NE corridor.

• Develop and implement integrated global HEOR strategies to support pipeline and lifecycle management programs with a US launch focus.
• Lead development of US RWD strategies and partnerships with academic consortia, claims databases, and health systems to support value demonstration, comparative effectiveness, and longitudinal outcomes studies.
• Design and implement real-world data analyses to understand and articulate the current patient demographics, treatment patterns, and outcomes.
• Develop AMCP value dossiers, economic modeling, narratives, and scientific publications to support value propositions.
• Serve as a key domain expert for payer engagement, providing evidence summaries and presentations that strengthen product positioning and formulary access.
• Engage and collaborate with external partners including payers, providers, and other access decision-makers to establish/maintain strong partnerships and gather insights.
• Lead the external dissemination of HEOR/RWE deliverables including publications, presentations, and professional conferences.
• Provide input to clinical development programs.
• Collaborate closely with partners on HEOR & RWE programs, ensuring coordinated evidence generation, cost-sharing, and data-sharing aligned to global commercialization goals.
• Represent HEOR in relevant governance meetings, advisory boards, and internal strategy sessions to shape business decisions through evidence-driven insight.

Qualifications

• PhD, PharmD, MPH, or Master’s in Health Economics, Outcomes Research, Epidemiology, or a related discipline.
• 8–12 years of HEOR/RWE experience in biotech, pharmaceutical organizations or consultancies with demonstrated success in pre-launch and commercialization phases.
• Therapeutic area expertise in metabolic, endocrine, or cardiometabolic diseases strongly preferred.
• Deep understanding of payer and evidence requirements in the U.S.
• Proficiency in RWD study design and analysis, and patient outcome measure development.
• Proven ability to communicate complex data to non-technical audiences, including payers, regulators, and cross-functional business leaders.
• Experience leading external collaborators, vendors, and cross-company joint HEOR initiatives.
• Publication track record and presentation experience at peer-reviewed scientific meetings.

Company Description

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a team in the U.S.